Finasteride and Post-Finasteride Syndrome
5-Alpha-Reductase Inhibitors and Persistent Sexual and Mood Effects
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA-approved; label updated (2012) on persistent sexual effects
Reference only. Not medical advice.
What can go wrong
Recognized on-treatment effects include reduced libido, erectile dysfunction, and ejaculatory disorders. The contested risk is persistence of sexual, depressive, anxiety, and cognitive symptoms after stopping. Pharmacovigilance analyses have flagged disproportionate reporting of sexual and neuropsychiatric events, and some reports note suicidality signals. Causality is not settled, and reporting bias is a real confounder, which is why this remains debated.
This is something to take to a clinician. The Atlas can tell you what is known about finasteride and post-finasteride syndrome in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Finasteride and dutasteride inhibit 5-alpha-reductase, lowering dihydrotestosterone for hair loss and benign prostatic hyperplasia. Beyond the recognized on-treatment sexual side effects, a contested constellation called post-finasteride syndrome describes sexual, mood, and cognitive symptoms reported to persist after stopping. In 2012 the FDA updated the label to note that erectile dysfunction and other sexual effects may continue after discontinuation. Causality and frequency of persistent symptoms remain debated, but the labeled warning and pharmacovigilance signals make this a documented safety topic.
A hair-loss and prostate drug at the center of a persistence debate.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
5-alpha-reductase converts testosterone to dihydrotestosterone, a potent androgen and a precursor in neurosteroid pathways. Inhibiting it shrinks the prostate and slows androgenetic hair loss but also lowers DHT systemically. Proposed mechanisms for persistent symptoms include lasting changes in androgen receptor expression and altered neurosteroid signaling, though these remain hypotheses rather than established cause.
Safety in detail
Finasteride can cause sexual side effects, and the FDA label notes some may persist after stopping. Men should be counseled before starting, and persistent sexual or mood symptoms, especially depression or suicidal thoughts, warrant prompt physician evaluation.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Counseling on potential sexual and mood effects before starting
- Sexual function and mood follow-up on and after treatment
- Discontinuation discussion if symptoms emerge
- Mental-health screening if depressive or suicidal symptoms appear
What people get wrong
Often saidSide effects always disappear the moment you stop
ActuallyThe FDA label itself notes sexual effects may continue after discontinuation in some men; the frequency is debated but not zero.
Often saidPost-finasteride syndrome is proven beyond doubt
ActuallyCausality and prevalence remain genuinely contested in the literature; strong patient reports coexist with confounding and reporting-bias concerns.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Mechanism
- Inhibits 5-alpha-reductase, lowering DHT
- 2012 FDA label
- Notes sexual effects may persist after stopping
- PFS
- Reported but contested persistent syndrome
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Finasteride and Post-Finasteride Syndrome. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA Propecia label update2012
FDA expanded the label to note sexual adverse effects, including erectile dysfunction, that may persist after discontinuation
Irwig pharmacovigilance analysis2022
Argued routine pharmacovigilance was slow to capture persistent sexual effects of finasteride
FAERS disproportionality analyses of finasterideestablished
Reported disproportionate sexual and neuropsychiatric adverse-event signals; interpretation debated